On Monday, Invivyd Inc. IVVD shares rallied on the heels of a brand new knowledge report involving a COVID-19 therapy.
The corporate is conducting an ongoing Section 1/2 trial of VYD2311, a monoclonal antibody (mAb) candidate. A proper estimate of in vivo half-life will not be but accessible for VYD2311 given the lengthy obvious half-life so far.
As of Day 65, serum concentrations stay excessive, doubtlessly considerably rising the noticed half-life of VYD2311 relative to pemivibart, the corporate’s monoclonal antibody remedy approved for the pre-exposure prophylaxis (prevention) of COVID‑19.
Additionally Learn: What’s Going On With COVID-19 Antibody Developer Invivyd Inventory On Friday?
Evaluation for the IM cohort (essentially the most superior cohort in time) is monitoring typically with the PK profile of adintrevimab, a earlier Invivyd mAb with an estimated in vivo half-life of 139 days.
PK evaluation of VYD2311 intravenous and subcutaneous cohorts at earlier timepoints, at both related doses subcutaneously or increased doses intravenously, are equally and encouragingly monitoring near the estimated curves for adintrevimab so far.
In vitro neutralization knowledge generated repeatedly on VYD2311 as a part of Invivyd’s industrial virology efforts show a median efficiency enchancment for VYD2311 of roughly 17-fold in comparison with pemivibart.
The mixed security, pharmacokinetics (PK), and virology knowledge for VYD2311, together with findings from Invivyd’s CANOPY Section 3 trial and former monoclonal antibody (mAb) research, counsel that VYD2311 might provide sturdy and long-lasting safety in opposition to COVID-19.
A single dose could present excessive protecting antibody ranges for six months to a 12 months or longer.
The corporate additionally reported preliminary fourth quarter 2024 Pemgarda (pemivibart) internet product income of $13.8 million. That’s 48% progress over Q3 2024 internet product income of $9.3 million.
The corporate’s preliminary ending 2024 money and money equivalents of $69.3 million.
Worth Motion: Invivyd inventory is up 72.8% eventually examine Tuesday.
Learn Subsequent:
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
